ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the model for end-stage liver disease score

Hepatology Research

Volumn 42, Issue 5, 2012, Pages 459-472

  Takaya, Hiroaki ^a   Uemura, Masahito ^a   Fujimura, Yoshihiro ^a   Matsumoto, Masanori ^a   Matsuyama, Tomomi ^a   Kato, Seiji ^a   Morioka, Chie ^a   Ishizashi, Hiromichi ^a   Hori, Yuji ^a   Fujimoto, Masao ^a   Tsujimoto, Tatsuhiro ^a   Kawaratani, Hideto ^a   Toyohara, Masahisa ^a   Kurumatani, Norio ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

ADAMTS13 activity; Child Turcotte Pugh score; Liver cirrhosis; Model for end stage liver disease score; Prognosis

Indexed keywords

ALBUMIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; ARTICLE; ASCITES; CHILD TURCOTTE PUGH SCORE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; SURVIVAL TIME;

EID: 84861319977     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00950.x     Document Type: Article

References (51)

1. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008; 28: 110-22.
2. Child CG, Turcotte JG. The liver and portal hypertension. In: Child CI, ed. Surgery and Portal Hypertension. Philadelphia: W.B. Saunders, 1964; 50-8.
3. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the esophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
4. Salerno F, Merli M, Cazzaniga M et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol 2002; 36: 494-500.
5. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
6. Yoo HY, Edwin D, Thuluvath PJ. Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am J Gastroenterol 2003; 98: 1395-9.
7. Northup PG, Sundaram V, Fallon MB et al. Coagulation in Liver Disease Group. Hypercoagulation and thrombophilia in liver disease. J Thromb Haemost 2008; 6: 2-9.
8. Amitrano L, Guardascione MA, Brancaccio V et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-41.
9. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-47.
10. Oka K, Tanaka K. Intravascular coagulation in autopsy cases with liver diseases. Thromb Haemost 1979; 42: 564-70.
11. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-99.
12. Fujimura Y, Matsumoto M, Yagi H, Yoshioka A, Matsui T, Titani K. Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome. Int J Hematol 2002; 75: 25-34.
13. Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS13 gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
14. Kokame K, Matsumoto M, Soejima K et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 2002; 99: 11902-7.
15. Furlan M, Robles R, Galbusera M et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84.
16. Tsai HM, Lian EC. Antibodies to von Willebrand factorcleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94.
17. Uemura M, Tatsumi K, Matsumoto M et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106: 922-4.
18. Suzuki M, Murata M, Matsubara Y et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun 2004; 313: 212-16.
19. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost 2006; 4: 1396-404.
20. Manea M, Kristoffersson A, Schneppenheim R et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2007; 138: 651-62.
21. Ferro D, Quintarelli C, Lattuada A et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23: 1377-83.
22. Albornoz L, Alvarez D, Otaso JC et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol 1999; 30: 451-5.
23. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966; 45: 645-57.
24. Peck-Radosavljevic M, Wichlas M, Zacherl J et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95: 795-801.
25. Schhffski P, Tacke F, Trautwein C et al. Thrombopoietin serum levels are elevated in patients hepatitis B/C infection compared with other causes of chronic liver diseases. Liver 2002; 22: 114-20.
26. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloproteinase that cleaves von Willebrand factor. Blood 2001; 98: 2730-5.
27. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138: 534-40.
28. Lisman T, Bongers TN, Adelmeijer J et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
29. Uemura M, Fujimura Y, Matsumoto M et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99: 1019-29.
30. Park YD, Yoshioka A, Kawa K et al. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant 2002; 29: 789-94.
31. Uemura M, Matsuyama T, Ishikawa M et al. Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2005; 29: 264S-71S.
32. Ko S, Okano E, Kanehiro H et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl 2006; 12: 859-69.
33. Yagita M, Uemura M, Nakamura T, Kunitomi A, Matsumoto M, Fujimura Y. Development of ADAMTS-13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J Hepatol 2005; 42: 420-1.
34. Henderson JM, Heymsfield SB, Horowitz J, Kutner MH. Measurement of liver and spleen volume by computed tomography. Radiology 1981; 141: 525-7.
35. Arroyo V, Ginès P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International ascites club. Hepatology 1996; 23: 164-76.
36. Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. N Engl J Med 1966; 274: 473-81.
37. Japanese Research Society for Portal Hypertension. The general rules for recording endoscopic findings on esophageal varices. Jpn J Surg 1980; 10: 329-37.
38. Kudo M, Chung H, Haji S et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40: 1396-405.
39. Mori Y, Wada H, Gabazza EC et al. Predicting response to plasma exchange in patients with thrombotic thrombocytopenic purpura with measurement of vWFcleaving protease activity. Transfusion 2002; 42: 572-80.
40. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle P. Deficiency activity of von Willebrand factorcleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103.
41. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 2006; 46: 1444-52.
42. Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-8.
43. Warren CM, Krzesinski PR, Greaser ML. Vertical agarose gel electrophoresis and electroblotting of high-molecularweight proteins. Electrophoresis 2003; 24: 1695-702.
44. Kasper CK, Aledort L, Aronson D et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
45. Schorer AE, Moldow CF, Rick ME. Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells. Br J Haematol 1987; 67: 193-7.
46. Tornai I, HIrsfalvi J, Boda Z, Udvardy M, Pfliegler G, Rak K. Endothelium releases more von Willebrand factor and tissue-type plasminogen activator upon venous occlusion in patients with liver cirrhosis than in normals. Haemostasis 1993; 23: 58-64.
47. Kume Y, Ikeda H, Inoue M et al. Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats. FEBS Lett 2007; 581: 1631-4.
48. Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Semin Hematol 2004; 41: 68-74.
49. Fujimura Y, Matsumoto M, Kokame K et al. Pregnancyinduced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. Br J Haematol 2009; 144: 742-54.
50. Claus RA, Bockmeyer CL, Budde U et al. Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239-47.
51. Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis 2005; 25: 171-80.